Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension

Journal of Pharmaceutical Sciences

Volumn 99, Issue 4, 2010, Pages 1774-1789

  Gupta, Vivek ^a   Rawat, Amit ^a   Ahsan, Fakhrul ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

PLGA microspheres; Polyvinyl alcohol (PVA); Pulmonary arterial hypertension (PAH); Pulmonary delivery

Indexed keywords

MICROSPHERE; POLYGLACTIN; POLYVINYL ALCOHOL; PROSTAGLANDIN E1;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; DRUG SYNTHESIS; FEASIBILITY STUDY; LUNG HOMOGENATE; LUNG LAVAGE; MALE; MAXIMUM PLASMA CONCENTRATION; NON INVASIVE PROCEDURE; NONHUMAN; PARTICLE SIZE; PULMONARY HYPERTENSION; RAT;

EID: 77949807384     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21946     Document Type: Article

References (43)

1. Gaine SP, Rubin LJ. 1998. Primary pulmonary hypertension. Lancet 352:719-725.
2. Martin KB, Klinger JR, Rounds SI. 2006. Pulmonary arterial hypertension: New insights and new hope. Respirology 11:6-17.
3. Humbert M, Sitbon O, Simonneau G. 2004. Treatment of pulmonary arterial hypertension. N Engl J Med 351:1425-1436.
4. Gomberg-Maitland M, Preston IR. 2005. Prostacyclin therapy for pulmonary arterial hypertension: New directions. Semin Respir Crit Care Med 26: 394-401.
5. Olschewski H, Rohde B, Behr J, Ewert R, Gessler T, Ghofrani HA, Schmehl T. 2003. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 124:1294-1304.
6. Voswinckel R, Ghofrani HA, Grimminger F, Seeger W, Olschewski H. 2006. Inhaled treprostinil [corrected] for treatment of chronic pulmonary arterial hypertension. Ann Intern Med 144:149-150.
7. Sandifer BL, Brigham KL, Lawrence EC, Mottola D, Cuppels C, Parker RE. 2005. Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation. J Appl Physiol 99:2363-2368.
8. Kunimoto F, Arai K, Isa Y, Koyano T, Kadoi Y, Saito S, Goto F. 1997. A comparative study of the vasodilator effects of prostaglandin E1 in patients with pulmonary hypertension after mitral valve replacement and with adult respiratory distress syndrome. Anesth Analg 85:507-513.
9. Shen J, He B, Wang B. 2005. Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension. Chest 128:714-719.
10. Sood BG, Delaney-Black V, Aranda JV, Shankaran S. 2004. Aerosolized PGE1: A selective pulmonary vasodilator in neonatal hypoxemic respiratory failure results of a phase I/II open label clinical trial. Pediatr Res 56:579-585.
11. Della Rocca G, Coccia C, Pompei L, Costa MG, Di Marco P, Pietropaoli P. 2008. Inhaled aerosolized prostaglandin E1, pulmonary hemodynamics, and oxygenation during lung transplantation. Minerva Anestesiol 74:627-633.
12. Meyer J, Theilmeier G, Van Aken H, Bone HG, Busse H, Waurick R, Hinder F, Booke M. 1998. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesth Analg 86:753-758.
13. Hollo G. 2007. The side effects of the prostaglandin analogues. Expert Opin Drug Saf 6:45-52.
14. Gu FG, Cui FD, Gao YL. 2005. Preparation of prostaglandin E1-hydroxypropyl-beta-cyclodextrin complex and its nasal delivery in rats. Int J Pharm 290:101-108.
15. Igarashi R, Takenaga M, Takeuchi J, Kitagawa A, Matsumoto K, Mizushima Y. 2001. Marked hypotensive and blood flow-increasing effects of a new lipo-PGE(1) (lipo-AS013) due to vascular wall targeting. J Control Release 71:157-164.
16. Feld S, Li G, Amirian J, Felli P, Vaughn WK, Accad M, Tolleson TR, Swenson C, Ostro M, Smalling RW. 1994. Enhanced thrombolysis, reduced coronary reocclusion and limitation of infarct size with liposomal prostaglandin E1 in a canine thrombolysis model. J Am Coll Cardiol 24:1382-1390.
17. Pan H, Kopeckova P, Liu J, Wang D, Miller SC, Kopecek J. 2007. Stability in plasmas of various species of HPMA copolymer-PGE1 conjugates. Pharm Res 24:2270-2280.
18. Huang Y, Marui A, Sakaguchi H, Esaki J, Arai Y, Hirose K, Bir SC, Horiuchi H, Maruyama T, Ikeda T, Tabata Y, Komeda M. 2008. Sustained release of prostaglandin E1 potentiates the impaired therapeutic angiogenesis by basic fibroblast growth factor in diabetic murine hindlimb ischemia. Circ J 72:1693-1699.
19. Ishihara T, Takahashi M, Higaki M, Takenaga M, Mizushima T,Mizushima Y. 2008. Prolonging the in vivo residence time of prostaglandin E(1) with biodegradable nanoparticles. Pharm Res 25:1686-1695.
20. Rawat A, Majumder QH, Ahsan F. 2008. Inhalable large porous microspheres of low molecular weight heparin: In vitro and in vivo evaluation. J Control Release 128:224-232.
21. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. 1997. Large porous particles for pulmonary drug delivery. Science 276:1868-1871.
22. Thomas C, Gupta V, Ahsan F. 2009. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int J Pharm 379: 41-50.
23. Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R, Langer R, Edwards DA. 1999. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 16:1735-1742.
24. Nakano J, Prancan AV, Morsy NH. 1973. Metabolism of prostaglandin E1 in stomach, jejunum chyle and plasma of the dog and the rat. Jpn J Pharmacol 23:355-361.
25. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. 1988. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48:4827-4833.
26. Thomas C, Rawat A, Bai S, Ahsan F. 2008. Feasibility study of inhaled hepatitis B vaccine formulated with tetradecylmaltoside. J Pharm Sci 97: 1213-1223.
27. Cirpanli Y, Unlu N, Calis S, Hincal AA. 2005. Formulation and in-vitro characterization of retinoic acid loaded poly (lactic-co-glycolic acid) microspheres. J Microencapsul 22:877-889.
28. Jeong YI, Song JG, Kang SS, Ryu HH, Lee YH, Choi C, Shin BA, Kim KK, Ahn KY, Jung S. 2003. Preparation of poly(DL-lactide-co-glycolide) microspheres encapsulating all-trans retinoic acid. Int J Pharm 259:79-91.
29. Lee SC, Oh JT, Jang MH, Chung SI. 1999. Quantitative analysis of polyvinyl alcohol on the surface of poly(D, L-lactide-co-glycolide) microparticles prepared by solvent evaporation method: Effect of particle size and PVA concentration. J Control Release 59:123-132.
30. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. 1999. Preparation of poly(DL-lactide-coglycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm 187:143-152.
31. Srinivasan C, Katare YK, Muthukumaran T, Panda AK. 2005. Effect of additives on encapsulation efficiency, stability and bioactivity of entrapped lysozyme from biodegradable polymer particles. J Microencapsul 22:127-138.
32. Yang YY, Chung TS, Ng NP. 2001. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 22: 231-241.
33. Mitchell JP, Nagel MW. 2003. Cascade impactors for the size characterization of aerosols from medical inhalers: Their uses and limitations. J Aerosol Med 16:341-377.
34. Ronneberger B, Kao WJ, Anderson JM, Kissel T. 1996. In vivo biocompatibility study of ABA triblock copolymers consisting of poly(L-lactic-co-glycolic acid) A blocks attached to central poly(oxyethylene) B blocks. J Biomed Mater Res 30:31-40.
35. Heya T, Okada H, Tanigawara Y, Ogawa Y, Toguchi H. 1991. Effect of counteranion of TRH and loading amount on control of TRH release from copoly(DL-lactic/glycolic acid) microspheres prepared by an in-water drying method. Int J Pharm 69:69-75.
36. Takada S, Yamagata Y, Misaki M, Taira K, Kurokawa T. 2003. Sustained release of human growth hormone from microcapsules prepared by a solvent evaporation technique. J Control Release 88:229-242.
37. Shive MS, Anderson JM. 1997. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28:5-24.
38. Labiris NR, Dolovich MB. 2003. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56:588-599.
39. Gabler F, Frauenschuh S, Ringe J, Brochhausen C, Gotz P, Kirkpatrick CJ, Sittinger M, Schubert H, Zehbe R. 2007. Emulsion-based synthesis of PLGA-microspheres for the in vitro expansion of porcine chondrocytes. Biomol Eng 24:515-520.
40. Ellis MJ, Chaudhuri JB. 2008. Human bone derived cell culture on PLGA flat sheet membranes of different lactide:glycolide ratio. Biotechnol Bioeng 101:369-377.
41. Hussain A, Majumder QH, Ahsan F. 2006. Inhaled insulin is better absorbed when administered as a dry powder compared to solution in the presence or absence of alkylglycosides. Pharm Res 23:138-147.
42. Xu H, Verbeken E, Vanhooren HM, Nemery B, Hoet PH. 2004. Pulmonary toxicity of polyvinyl chloride particles after a single intratracheal instillation in rats. Time course and comparison with silica. Toxicol Appl Pharmacol 194:111-121.
43. Hussain A, Ahsan F. 2005. State of insulin self-association does not affect its absorption from the pulmonary route. Eur J Pharm Sci 25:289-298.